Compare Incyte Corporation (INCY) vs Macerich Company (The) Common Stock (MAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Macerich Company (The) Common Stock — how do they compare? Incyte Corporation trades at $115.61 (market cap $22.63B), while Macerich Company (The) Common Stock trades at $22.33 (market cap $6.29B). The key difference: Incyte Corporation is far larger — about 3.6× Macerich Company (The) Common Stock's market cap, and Macerich Company (The) Common Stock pays a 3.07% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Macerich Company (The) Common Stock for 0 Days on average.
| INCY | MAC | |
|---|---|---|
Market Cap | $22.63B | $6.29B |
Volume | 1,869,988 | 3,158,142 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $26.51 |
52-Week Low | $86.17 | $16.20 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.13B | $10.97B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $108.62, down 2.46% on the day, with a bearish technical signal despite strong fundamental performance. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline developments support growth beyond JAKAFI exclusivity. Analyst consensus remains positive with a $133.14 price target, though technical indicators show selling pressure near-term.
The outlook balances strong fundamentals against technical weakness. Upside potential exists from pipeline execution and $4B sales target, but risks include JAKAFI patent expiration post-2029 and current bearish momentum. With 52% buy ratings and solid cash flow generation, the stock offers value at current levels for patient investors despite near-term volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Macerich Company (The) Common Stock
The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.
Read more on MAC →
